Press release about the positive opinion of the CHMP for Fablyn (lasofoxifene):
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE SUMMARY OF POSITIVE OPINION for
International Nonproprietary Name (INN): lasofoxifene
On 18 December 2008 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending to grant a marketing authorisation for the medicinal product FABLYN, 500 μg, film-coated tablets intended for treatment of osteoporosis in postmenopausal women at increased risk of fracture. The applicant for this medicinal product is Pfizer Limited.
The active substance of FABLYN is lasofoxifene, a Selective Estrogen Receptor Modulator (ATC code not yet assigned) whose biological actions areContinue Reading